It was a slow week, but not exactly a quiet week. The US Food and Drug Administration approved Heron Therapeutics, Inc.’s Zynrelef, an extended-release dual-acting local anesthetic that could forestall the need for narcotic analgesia after some surgeries – an incremental step in the multi-front campaign against opioid abuse.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?